Blood
Articles in this Issue
First report: A novel deep intronic mutation and treatment using hetrombopag olamine of a patient with MYH9 syndrome and immune thrombocytopenia
Abstract Introduction: MYH9-related diseases (MYH9-RD), caused by pathogenic variants in the MYH9 gene through an autosomal dominant inherit...
Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM)
Abstract Introduction IMiDs (eg, lenalidomide, pomalidomide) are approved for the treatment of patients with MM and other hematologic malign...
Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial
Abstract Introduction: Hetrombopag has been approved for chronic primary immune thrombocytopenia (ITP) (duration >12 months). However...
Prognostic value of baseline metabolic tumor volume from lysa ro-CHOP trial inpatients with previously untreated peripheral T-cell lymphoma
Abstract Background: Peripheral T-cell lymphomas (PTCLs) are aggressive lymphoid malignancies with poor outcomes and lim...
An unseen crisis: The gap between recommendations and reality
Abstract Individuals with sickle cell disease (SCD) face significant disparities in accessing recommended healthcare, particularly in rural...
Disrupting monocytic AML and monocytic leukemia stem cells with a novel cladribine regimen: From bench to bedside
Abstract Recent studies, including our own, have demonstrated that the heterogeneity of leukemia stem cells (LSCs) drives therapeutic resist...
Comparative real-world outcomes of bispecific antibodies versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort analysis
Abstract Background Bispecific antibodies (BsAbs) in relapsed/refractory multiple myeloma (RRMM) have shown high response rates in patients...
Is hydroxyurea treatment associated with an increased risk of malignancy in sickle cell disease? a propensity-matched analysis of 27,854 patients in the real world
Abstract Background: Hydroxyurea (HU) is a key therapy for sickle cell disease (SCD) that aims to reduce the frequency of vaso-occlusive cri...
Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis
Abstract Introduction AL amyloidosis is an incurable plasma cell disorder where misfolded light chains (LC) form toxic fibrils that deposit i...
Letermovir cytomegalovirus prophylaxis in hematopoietic-cell transplantation; Real world evidence from high endemic regions.
Abstract Introduction: Cytomegalovirus (CMV) reactivation remains a significant complication following allogeneic hematopoietic-cell transpl...
Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study
Abstract Introduction: MCL is a rare, incurable subtype of B-cell non-Hodgkin lymphoma characterized by a continuous pattern of relapse afte...
Development of novel small-molecule DDX5 inhibitors for treating relapsed and/or refractory multiple myeloma
Abstract Multiple myeloma (MM) is an age-dependent neoplasm characterized by clonal expansion of malignant antibody-producing bone marrow pl...
Bone matters: Defining the burden of skeletal disease in telomere biology disorders
Abstract Introduction: Telomere biology disorders (TBDs) are caused by germline pathogenic or likely pathogenic variants in telomere mainten...
Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder characterized by chronic complement-mediated hemolysis. Treatment invo...
IV diphenhydramine is not associated with poor outcomes among hospitalized people with sickle cell disease.
Abstract Among people living with sickle cell disease (SCD), acute chest syndrome (ACS) is a potentially life-threatening complication that...
Development of synthetic introns for selective elimination of U2AF1 mutant MDS
Abstract Mutations affecting the RNA splicing factors SF3B1, U2AF1, and SRSF2 are the most common class of genetic alterations in MDS. Patie...
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Abstract Background: Mutations in exon 9 of calreticulin (mutCALR) are found in ~30% of pts with MF. INCA033989 (‘989‘), a novel, fully huma...
QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis
Abstract Background: QHRD107, a potent CDK9 inhibitor, has demonstrated promising activity in relapsed/refractory acute myeloid leukemia (R/...
Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan
Abstract Introduction: Bruton tyrosine kinase inhibitors (BTKis) have transformed the treatment landscape for CLL, offering significant impr...
Impact of blood transfusion on clinical outcomes in patients hospitalized with acute promyelocytic leukemia: A nationwide analysis
Abstract Background: Acute promyelocytic leukemia (APL) is a distinct and aggressive subtype of acute myeloid leukemia c...
Multiple myeloma with concomitant chronic lymphocytic leukemia: Common or distinct clonal origin?
Abstract Background: Multiple myeloma (MM) is a plasma cell (PC) neoplasm affecting cells of the final stage of B-cell differentiation while...
Identification of therapeutic vulnerabilities in FLT3-mutated AML through customized CRISPR screens
Abstract Background: Acute myeloid leukemia (AML) is a genetically diverse and aggressive blood cancer. FLT3 mutations occur in ~30% of AML c...
Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data
Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Despite improved prognosis w...
Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies
Abstract Introduction: Patients with high-risk myelofibrosis (MF; Dynamic International Prognostic Scoring System [DIPPS] score of 5-6) have...
Inhibition of FSP1 enhances venetoclax induced cell death in Acute Myeloid Leukemia by the ferroptosis pathway
Abstract Objective Acute myeloid leukemia (AML) is the most common malignant hematological neoplasm in adults, and the combination of veneto...